Does milder interstitial cystitis progress to an inevitable bad end with no apparent option but diversion?
New York-Does milder interstitial cystitis progress to an inevitable bad end with no apparent option but diversion? No, believes Jerry Blaivas, MD, who took a close look at cases with "end-stage" bladder seen at his institution over the past decade. By looking at the natural history of these cases, he aimed not only to determine whether cases of painful bladder syndrome progress this far but also to look for what might cause these severe cases and determine what treatment is appropriate.
Patients also had to show no evidence of malignancy and have had no pelvic radiation. (One patient was included who had undergone three bladder biopsies with negative results but turned out to have a poorly differentiated bladder carcinoma.)
All of the patients had pyuria and microhematuria and marked inflammation on every cystoscopy. They all had marked urinary frequency, bladder capacities were tiny, and compliance was low (means of 20 voids per day, 120 mL maximum voided volume, 173 mL cystometrogram bladder capacity, and 8 mL/cm H2O bladder compliance, respectively).
Not only was bladder compliance low for 20 patients (75%), but nine (36%) also had vesicoureteral reflux, 14 (56%) had hydronephrosis, and eight (32%) had renal failure.
PSMA levels linked to tumor biology, treatment sensitivity in treatment-naïve prostate cancer
September 20th 2024“Our findings suggest that high PSMA tumors may respond better to AR-targeting therapies. Tumors with low PSMA possess markers of cancer stem cells and are associated with resistance to radiotherapy," the authors write.
PSMA-PET by PROMISE criteria shows prognostic value across prostate cancer continuum
September 20th 2024“Our PPP nomograms accurately stratify high- vs. low-risk groups for overall survival in early and late stages of prostate cancer and yield better prediction than established clinical risk tools," wrote the authors.